MedTrace Logo

Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease

NCT05213156 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2022-04-18

No results posted yet for this study

Summary

After topical installation of one drop of 0.3% commercially available ofloxacin (Oxatrex®) four times at intervals of 15min in catarract patients with Dry Eye Disease, aqueous humour samples will be collected intraoperatively, one hour after the last installation. Concentration of ofloxacin in aqueous humour will be measured by HPLC-MS/MS.

Conditions

Interventions

DRUG

Oxatrex

0.3% ofloxacin eye drops in single doses

Sponsors & Collaborators

  • University of Patras

    collaborator OTHER

  • University Hospital of Patras

    lead OTHER

Principal Investigators

  • Constantine D. Georgakopoulos, MD, PhD · University Hospital of Patras

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-24
Primary Completion
2022-01-24
Completion
2022-01-24

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05213156 on ClinicalTrials.gov